Email this article 
Prospecting Marine Natural Products as the Disease-Modifying Treatment of Alzheimer’s Diseases
Abstract
Alzheimer's disease (AD) is a severe and high costs health problem all over the world. To date, there is no therapy capable of curing AD, making drug discovery a challenging and intriguing field to explore. Targeting marine natural products (MNPs) as a source of drug leads is a suitable choice considering the content of bioactive compounds and promising pharmacological benefits. This article aims to look at MNPs with prospects in several prime targets in AD pathology to cure AD. Marine vertebrates (fishes), marine invertebrates (sponges, tunicates, ascidian, clams, scallops, sand dollars, crabs, cockle, sea cucumber, shrimp, bryozoa, marine worm), algae/seaweed, and marine microorganisms (marine fungi, bacterium, dinoflagellata, microalgae) can be potentially used as disease-modifying treatments (DMTs) for AD. By targeting multiple aspects of AD pathology, these MNPs offer a multifaceted approach to treating and potentially modifying the disease course. This result is an intriguing gap for researchers in the discovery and development of new drugs that can improve AD pathology.
Keywords
Full Text:
PDFReferences
Altmann KH. (2017). Drugs from the Oceans: Marine Natural Products as Leads for Drug Discovery. Chimia (Aarau), 71(10): 646-652. doi.org/10.2533/chimia.2017.646.
B?la?a AF, Chircov C, Grumezescu AM. (2020). Marine Biocompounds for Neuroprotection—A Review. Marine Drugs, 18(6): 1-24. doi.org/10.3390/md18060290.
Bi D, Li X, Li T, Li X, Lin Z, Yao L, Li H, Xu H, Hu Z, Zhang Z, Liu Q, Xu X. (2020). Characterization and Neuroprotection Potential of Seleno-Polymannuronate. Front Pharmacol. 20: 11-21. doi.org/10.3389/fphar.2020.00021.
Botelho MJ, Milinovic J, Bandarra NM, Vale C. (2020). Alzheimer’s Disease and Toxins Produced by Marine Dinoflagellates: An Issue to Explore. Marine Drugs, 20(4):253. doi.org/10.3390/md20040253.
Cacabelos, R. (2022). What have we learnt from past failures in Alzheimer’s disease drug discovery?. Expert Opinion on Drug Discovery, 17(4): 309–323. doi.org/10.1080/17460441.2022.2033724.
Carroll AR, Copp BR, Davis RA, Keyzers RA, Prinsep MR. (2021). Marine natural products. Natural Product Reports, 38(2): 362-413. doi.org/10.1039/D0NP00089B.
Cummings JL, Tong G, Ballard C. (2019). Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options. J Alzheimers Dis, 67(3): 779-794. doi.org/10.3233/JAD-180766.
De Plano LM, Calabrese G, Rizzo MG, Oddo S, Caccamo A. (2023). The Role of the Transcription Factor Nrf2 in Alzheimer’s Disease: Therapeutic Opportunities. Biomolecules, 13(3):549. doi.org/10.3390/biom13030549.
Dong Y, Li X, Cheng J, Hou L. (2019). Drug development for alzheimer’s disease: Microglia induced neuroinflammation as a target?. Int J Mol Sci, 20(3): 558. doi.org/10.3390/ijms20030558.
Ferreira I, Rauter AP, Bandarra NM. (2022). Marine Sources of DHA-Rich Phospholipids with Anti-Alzheimer Effect. Marine Drugs. 2022, 20(11): 662. doi.org/10.3390/md20110662.
Hu D, Jin Y, Hou X, Zhu Y, Chen D, Tai J, Chen Q, Shi C, Ya J, Wu M, et al. (2023). Application of Marine Natural Products Against Alzheimer’s Disease: Past, Present and Future. Marine Drugs, 21(1): 43. doi.org/10.3390/md21010043.
Iannuzzi C, Borriello M, D'Agostino A, Cimini D, Schiraldi C, Sirangelo I. (2019). Protective effect of extractive and biotechnological chondroitin in insulin amyloid and advanced glycation end product-induced toxicity. J Cell Physiol, 234(4): 3814-3828. doi.org/10.1002/jcp.27153.
Jo S-L, Yang H, Jeong K-J, Lee H-W, Hong E-J. (2023). Neuroprotective Effects of Ecklonia cava in a Chronic Neuroinflammatory Disease Model. Nutrients. 15(8): 2007. doi.org/10.3390/nu15082007.
Kabir MT, Uddin MS, Jeandet P, Emran TB, Mitra S, Albadrani GM, Sayed AA, Abdel-Daim MM, Simal-Gandara J. (2021). Anti-Alzheimer’s Molecules Derived from Marine Life: Understanding Molecular Mechanisms and Therapeutic Potential. Marine Drugs, 19(5):251. doi.org/10.3390/md19050251
Kim CK, Lee YR, Ong L, Gold M, Kalali A, Sarkar J. (2022). Alzheimer's Disease: Key Insights from Two Decades of Clinical Trial Failures. J Alzheimers Dis, 87(1): 83-100. doi.org/10.3233/JAD-215699.
Koelsch G. (2017). BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer’s Disease Pathology. Molecules, 22(10):1723. doi.org/10.3390/molecules22101723.
Kong Y, Liu C, Zhou Y, Qi J, Zhang C, Sun B, Wang J, Guan Y. (2020). Progress of RAGE Molecular Imaging in Alzheimer’s Disease. Front. Aging Neurosci, Alzheimer's Disease and Related Dementias, 2020(12): 1-9. doi.org/10.3389/fnagi.2020.00227.
Li DD, Zhang YH, Zhang W, Zhao P. (2019). Meta-analysis of randomized controlled trials on the efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease. Front Neurosci, 2019(13): 1-18. doi.org/10.3389/fnins.2019.00472.
Lyu, C, Chen T, Qiang B, Liu N, Wang H, Zhang L, Liu Z. (2021). CMNPD: a Comprehensive Marine Natural Products Database Towards Facilitating Drug Discovery from the Ocean. Nucleic Acids Res, 49(1), 509-515. doi: 10.1093/nar/gkaa763.
Martins M, Silva R, M. M. Pinto M, Sousa E. (2020). Marine Natural Products, Multitarget Therapy and Repurposed Agents in Alzheimer’s Disease. Pharmaceuticals, 13(9): 242. doi.org/10.3390/ph13090242.
Mehta D, Jackson R, Paul G, Shi J, Sabbagh, M. (2017). Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010-2015. Expert Opinion on Investigational Drugs, 26(6): 735–739. doi.org/10.1080/13543784.2017.1323868.
Montaser R, Luesch H. (2011). Marine natural products: a new wave of drugs? Future Med Chem, 3(12):1475-89. doi.org/10.4155/fmc.11.118.
Mycroft-West CJ, Devlin AJ, Cooper LC, Guimond SE, Procter P, Guerrini M, Miller GJ, Fernig DG, Yates EA, Lima MA, et al. (2021). Glycosaminoglycans from Litopenaeus vannamei Inhibit the Alzheimer’s Disease ? Secretase, BACE1. Marine Drugs, 19(4): 203. doi.org/10.3390/md19040203
Nugraha AS, Firli LN, Rani DM, et al. (2023). Indonesian Marine and Its Medicinal Contribution. Nat. Prod. Bioprospect, 13(38): 1-27. doi.org/10.1007/s13659-023-00403-1.
Osama A, Zhang J, Yao J, Yao X, Fang J. (2020). Nrf2: a dark horse in Alzheimer's disease treatment. Ageing Research Reviews, 64: 1-45. doi.org/10.1016/j.arr.2020.101206.
Park SK, Kang JY, Kim JM, Yoo SK, Han HJ, Chung DH, Kim D-O, Kim G-H, Heo HJ. (2019). Fucoidan-Rich Substances from Ecklonia cava Improve Trimethyltin-Induced Cognitive Dysfunction via Down-Regulation of Amyloid ? Production/Tau Hyperphosphorylation. Marine Drugs, 17(10): 591. doi.org/10.3390/md17100591
Reddy VP, Aryal P, Soni P. (2023). RAGE Inhibitors in Neurodegenerative Diseases. Biomedicines, 11(4):1131. doi.org/10.3390/biomedicines11041131.
Rivarti AW, Saputri LO, Harahap HS, Permatasari, L. (2023). Alzheimer’s disease from a diabetic brain: Exploring the molecular process to determine the potential therapy target from marine sources. Pharmacy Education, 23(4): 189-195. doi.org/10.46542/pe.2023.234.189195.
Sayas CL, Ávila J. (2021). GSK-3 and Tau: A Key Duet in Alzheimer’s Disease. Cells. 10(4): 721. doi.org/10.3390/cells10040721
Shatshat AL, Pham AT, Rao PPN. (2019). Interactions of polyunsaturated fatty acids with amyloid peptides A?40 and A?42. Archives of Biochemistry and Biophysics, 663(15): 34-43. doi.org/10.1016/j.abb.2018.12.027.
Silva M, Seijas P, Otero P. (2021). Exploitation of Marine Molecules to Manage Alzheimer's Disease. Mar Drugs, 19(7): 373. doi.org/10.3390/md19070373.
Stevenson, ME, Hebron M, Liu X, Kavulu B, Wolf C, Moussa, CEH. (2022). Inhibiting tyrosine kinase c-KIT as a therapeutic strategy for Alzheimer’s Disease. Alzheimer's Dement., 18(10): 1. doi.org/10.1002/alz.068944
Wang R, Reddy PH. (2017). Role of Glutamate and NMDA Receptors in Alzheimer's Disease. J Alzheimers Dis. 57(4): 1041-1048. doi: 10.3233/JAD-160763.
Xia Y, Sorrentino ZA, Kim JD, Strang KH, Riffe CJ, Giasson BI. (2019). Impaired tau–microtubule interactions are prevalent among pathogenic tau variants arising from missense mutation tau mutants impair microtubule interaction. Journal of Biological Chemistry. 294 (48): 18488-18503. doi.org/ 10.1074/jbc.RA119.010178
Yiannopoulou KG, Anastasiou AI, Zachariou V, Pelidou SH. (2019). Reasons for Failed Trials of Disease-Modifying Treatments for Alzheimer Disease and Their Contribution in Recent Research. Biomedicines, 7(4):97. doi.org/10.3390/biomedicines7040097.
DOI: https://doi.org/10.14421/biomedich.2024.132.433-441
Refbacks
- There are currently no refbacks.
Copyright (c) 2024 Legis Ocktaviana Saputri, Herpan Syafii Harahap, Arina Windri Rivarti, Fitriannisa Faradina Zubaidi, Fitriannisa Faradina Zubaidi
Biology, Medicine, & Natural Product Chemistry |
|
